Entering text into the input field will update the search result below

GlaxoSmithKline plc (GSK) Presents at Cowen 41st Annual Health Care Conference (Transcript)

Mar. 01, 2021 7:46 PM ETGSK plc (GSK), GLAXF1 Comment
SA Transcripts profile picture
SA Transcripts

GlaxoSmithKline plc (NYSE:GSK) Cowen 41st Annual Health Care Conference March 1, 2021 12:20 PM ET

Company Participants

Dr. Hal Barron - Chief Scientific Officer, President of R&D

Conference Call Participants

Steve Scala - Cowen and Company

Steve Scala

Good afternoon, and welcome to this session, featuring GlaxoSmithKline at Cowen's 41st Annual Healthcare Conference. We're very, very pleased to have with us Dr. Hal Barron, who is the Chief Scientific Officer and President of R&D at GlaxoSmithKline. Hal, thanks for taking away from your journey to transform GSK this time to be with us. We're very, very appreciative of that.

Maybe we can start out by asking a high-level question on your thoughts on the progress being made within GSK R&D since you came on board, what would you say has gone very well? And what would you say has gone less well?

Dr. Hal Barron

Well, thanks, Steve, for inviting me. It's a pleasure to be here. Yes. Let me start at the high-level question. Let me just recount a few things that I think we've been focused on and I think are going relatively well. In 2020 alone, I'll start there, although I think we've had some significant progress before that. But just in '20, last year alone, we had 9 approvals, actually, and 4 new molecular entities approved in a given year, which is pretty impressive for any company and certainly in my career. We also had 9 pivotal study starts, which will hopefully ultimately end up unblinding and being positive and leading to new medicines for patients. 2021, it's obviously early, but we've already had some success as Cabenuva was approved in the U.S., and we're now submitting that for every 2 month dosing. We started the Phase III in the RSV older adults trial, and we'll get to that in a little later, if you want to talk about the science behind that, and the opportunity that might have for patients and the

Recommended For You

Comments (1)

Just words

GSK continue to destroy capital. If it wasn’t for the div I’d be long gone at a big loss
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About GSK

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on GSK

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.